At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Nov 9, 2026 at 08:00 ET
AEON Biopharma submitted an IND to the FDA for a CMAP pharmacodynamic study of its ABP-450 biosimilar to BOTOX, following a recent Type 2b meeting. The study is designed to generate comparative evidence of neuromuscular activity, with initiation expected in Q1 2027. The filing is a procedural milestone in the biosimilar development pathway, with no financial data or regulatory decision announced.
- AEON submitted an IND for a CMAP pharmacodynamic study comparing ABP-450 to BOTOX.
- The submission follows a Biosimilar Biological Product Development Type 2b meeting with the FDA.
- Study initiation expected in Q1 2027.
- AEON is pursuing a 351(k) biosimilar pathway with a totality-of-evidence strategy that may avoid a standalone comparative efficacy study.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access